Participants: Darnitsa Pharmaceuticals CEO Gleb Zagorii and Darnitsa Pharmaceuticals Corporate Finance Director Mykhaylo Chupryna. Roman Nasirov, Head of Sales & Trading, Concorde Capital. November 03, 2009 at 5pm Kyiv time (3pm London time)

1. outline of the company’s current business model
2. impact of A/H1N1 outbreak in Ukraine
3. review of 1H09 financial results
4. 2009 financial projections
5. 2010 market view and prospects
6. future plans: acquisitions, mergers, sale, share placements

About the company: Darnitsa Pharmaceuticals (Nord Star Pharmashare, 4SI1 GR) is the largest Ukrainian producer of pharmaceuticals, with the fourth largest domestic market share after three foreign players. In 1H09, Darnitsa increased its net income 85% yoy to UAH 76.3 ths, EBITDA 51% yoy to UAH , and net sales 15% yoy to UAH . The company is benefiting from rising prices for imported drugs (70% of overall market), which are allowing it to boost its own prices and margins. The company is debt free and has a strong cash balance.